120
Participants
Start Date
January 31, 2006
Study Completion Date
January 31, 2008
hCRF
hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
placebo hCRF
placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
Weill Medical College of Cornell University, New York
Dent Neurologic Institute, Amherst
Wake Forest University, Winston-Salem
Winship Cancer Institute, Emory University, Atlanta
Moffitt Cancer Center and Research, Tampa
Vanderbilt University Medical Center, Nashville
Methodist Healthcare - University Hospital, Memphis
University Hematology Oncology Care, LLC, Cincinnati
The Ohio State University, Columbus
Good Samaritan Hospital, Cincinnati
Field Neurosciences Institute, Saginaw
University of Wisconsin, Madison
Evanston Northwestern Healthcare, Evanston
Northwestern University, Feinberg School of Medicine, Chicago
University of Colorado Cancer Center, Aurora
Barrow Neurological Institute, Phoenix
UC San Diego Cancer Center, La Jolla
Hoag Memorial Hospital Presbyterian, Newport Beach
Stanford University Medical Center, Palo Alto
UC Davis Medical Center, Sacramento
Oregon Clinic, Portland
Beth Israel Deaconess Med Center, Boston
Neurology Group of Bergen County, Ridgewood
Medical College of Wisconsin, Milwaukee
Cross Cancer Institute, Edmonton
Ottawa Regional Cancer Centre, Ottawa
Lead Sponsor
Collaborators (1)
Neurobiological Technologies
INDUSTRY
Celtic Pharma Development Services
INDUSTRY